Quantification of NG2-positivity for the precise prediction of KMT2A gene rearrangements in childhood acute leukemia.
Adolescent
Antigens
/ genetics
Biomarkers, Tumor
/ genetics
Child
Child, Preschool
Female
Gene Rearrangement
Genetic Testing
/ methods
Histone-Lysine N-Methyltransferase
/ genetics
Humans
Infant
Male
Myeloid-Lymphoid Leukemia Protein
/ genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ diagnosis
Proteoglycans
/ genetics
KMT2A
NG2
childhood acute leukemia
flow cytometry
Journal
Genes, chromosomes & cancer
ISSN: 1098-2264
Titre abrégé: Genes Chromosomes Cancer
Pays: United States
ID NLM: 9007329
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
19
06
2020
revised:
26
10
2020
accepted:
27
10
2020
pubmed:
3
11
2020
medline:
12
1
2022
entrez:
2
11
2020
Statut:
ppublish
Résumé
It has long been known that there is a link between neuron glial antigen 2 (NG2) surface expression and KMT2A gene rearrangements in acute leukemia (AL). However, the exact levels of NG2 positivity that predict the presence of KMT2A rearrangement are not known. The current study focuses on a cohort of 505 pediatric AL patients who showed any level of positive NG2 expression (greater than 1% of cells) for whom comprehensive genetic data were available. NG2 expression was measured as either the percentage of positive cells or the number of molecules on the cell surface. KMT2A gene rearrangements were identified by FISH. The fusion partner was detected with RT-PCR, LDI-PCR or anchored multiplex PCR followed by high-throughput sequencing. KMT2A-positive samples comprised a substantial proportion of the NG2-positive cohort (180 of 505, 36%), with a total of 19 different types of translocation. Despite its occurrence in other AL genetic subgroups, NG2 expression was significantly increased in AL patients with KMT2A rearrangements in terms of both the cell percentage and number of molecules per cell. The threshold levels (TL) for NG2-positivity were established by ROC analysis of the whole cohort and separately for children less than 1 years old and older with lymphoblastic (ALL) and myeloid (AML) leukemia. The lowest TL was defined in infants with ALL (7%), while in older children, the threshold was higher (12%). In AML patients, the situation was reversed, with 28% NG2-positivity in infants and 14% in patients >1 year old. The defined TLs resulted in improved diagnostic performance compared to the conventional thresholds of 10% and 20% for all patient groups.
Substances chimiques
Antigens
0
Biomarkers, Tumor
0
KMT2A protein, human
0
Proteoglycans
0
chondroitin sulfate proteoglycan 4
0
Myeloid-Lymphoid Leukemia Protein
149025-06-9
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
88-99Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Meyer C, Burmeister T, Groger D, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32(2):273-284.
Creutzig U, Zimmermann M, Reinhardt D, et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer. 2016;122(24):3821-3830.
Mullighan CG. Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest. 2012;122(10):3407-3415.
Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114(12):2489-2496.
Chessells JM, Harrison CJ, Kempski H, et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC childhood leukaemia working party. Leukemia. 2002;16(5):776-784.
Tsaur GA, Fleischman EW, Popov AM, Fechina LG, Rumyantsev SA. Genetic heterogeneity of infant acute leukemias. Onkogematologiya. 2016;11(1):14-23.
Rao RC, Dou Y. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer. 2015;15(6):334-346.
Yokoyama A. Molecular mechanisms of MLL-associated leukemia. Int J Hematol. 2015;101(4):352-361.
Chen X, Cherian S. Acute myeloid Leukemia Immunophenotyping by flow cytometric analysis. Clin Lab Med. 2017;37(4):753-769.
Qazi S, Uckun FM. Gene expression profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets. Br J Haematol. 2010;149(6):865-873.
Stam RW, Schneider P, Hagelstein JA, et al. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood. 2010;115(14):2835-2844.
Zangrando A, Dell'orto MC, Te Kronnie G, Basso G. MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures. BMC Med Genomics. 2009;2:36.
Zerkalenkova E, Lebedeva S, Kazakova A, et al. A case of pediatric acute myeloid leukemia with t(11;16)(q23;q24) leading to a novel KMT2A-USP10 fusion gene. Genes Chromosomes Cancer. 2018;57(10):522-524.
Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UKMedical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010;11(5):429-438.
Schwartz S, Rieder H, Schlager B, Burmeister T, Fischer L, Thiel E. Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(−)/CD24(−)/CD65s(+)/CD15(+) B-cell phenotype. Leukemia. 2003;17(8):1589-1595.
Wuchter C, Harbott J, Schoch C, et al. Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1. Leukemia. 2000;14(7):1232-1238.
Hrusak O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia. 2002;16(7):1233-1258.
Behm FG, Smith FO, Raimondi SC, Pui CH, Bernstein ID. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood. 1996;87(3):1134-1139.
Smith FO, Rauch C, Williams DE, et al. The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood. 1996;87(3):1123-1133.
Hilden JM, Smith FO, Frestedt JL, et al. MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. Blood. 1997;89(10):3801-3805.
Mauvieux L, Delabesse E, Bourquelot P, et al. NG2 expression in MLL rearranged acute myeloid leukaemia is restricted to monoblastic cases. Br J Haematol. 1999;107(3):674-676.
Zangrando A, Intini F, te Kronnie G, Basso G. Validation of NG2 antigen in identifying BP-ALL patients with MLL rearrangements using qualitative and quantitative flow cytometry: a prospective study. Leukemia. 2008;22(4):858-861.
Dworzak MN, Buldini B, Gaipa G, et al. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2018;94(1):82-93.
Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9(10):1783-1786.
Novikova IA, Verzhbitskaya TY, Movchan LV, Tsaur GA, Belevtsev MV, Popov AM. Russian-belarusian multicenter group standard guidelines for childhood acute lymphoblastic leukemia flow cytometric diagnostics. Onkogematologiya. 2018;13(1):73-82.
Kalina T, Flores-Montero J, van der Velden VH, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986-2010.
den Nijs JI, Gonggrijp HS, Augustinus E, Leeksma CH. Hot bands: a simple G-banding method for leukemic metaphases. Cancer Genet Cytogenet. 1985;15(3-4):373-374.
ISCN. 2016 an International System for Human Cytogenomic Nomenclature. Basel, Switzerland: Karger Publishers; 2016.
Jansen MW, van der Velden VH, van Dongen JJ. Efficient and easy detection of MLL-AF4, MLL-AF9 and MLL-ENL fusion gene transcripts by multiplex real-time quantitative RT-PCR in TaqMan and LightCycler. Leukemia. 2005;19(11):2016-2018.
Burmeister T, Meyer C, Groger D, Hofmann J, Marschalek R. Evidence-based RT-PCR methods for the detection of the 8 most common MLL aberrations in acute leukemias. Leuk Res. 2015;39(2):242-247.
Prasad R, Gu Y, Alder H, et al. Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute myeloid leukemias with the t(6;11) chromosome translocation. Cancer Res. 1993;53(23):5624-5628.
Zerkalenkova E, Lebedeva S, Kazakova A, et al. Acute myeloid leukemia with t(10;11)(p11-12;q23.3): results of Russian Pediatric AML registration study. Int J Lab Hematol. 2019;41(2):287-292.
Suzukawa K, Shimizu S, Nemoto N, Takei N, Taki T, Nagasawa T. Identification of a chromosomal breakpoint and detection of a novel form of an MLL-AF17 fusion transcript in acute monocytic leukemia with t(11;17)(q23;q21). Int J Hematol. 2005;82(1):38-41.
Mitani K, Kanda Y, Ogawa S, et al. Cloning of several species of MLL/MEN chimeric cDNAs in myeloid leukemia with t(11;19)(q23;p13.1) translocation. Blood. 1995;85(8):2017-2024.
Meyer C, Schneider B, Reichel M, et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci U S A. 2005;102(2):449-454.
Meyer C, Lopes BA, Caye-Eude A, et al. Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions. Leukemia. 2019;33(9):2306-2340.
Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe against cancer program. Leukemia. 2003;17(12):2318-2357.
Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561-577.
Weinstein S, Obuchowski NA, Lieber ML. Clinical evaluation of diagnostic tests. AJR Am J Roentgenol. 2005;184(1):14-19.
Matveeva E, Kazakova A, Olshanskaya Y, et al. A new variant of KMT2A(MLL)-FLNA fusion transcript in acute myeloid leukemia with ins(X;11)(q28;q23q23). Cancer Genet. 2015;208(4):148-151.
Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111(8):3941-3967.
Stetler-Stevenson M, Davis B, Wood B, Braylan R. 2006 Bethesda international consensus conference on flow cytometric Immunophenotyping of Hematolymphoid neoplasia. Cytometry B Clin Cytom. 2007;72(Suppl 1):S3.
de Nully Brown P, Jurlander J, Pedersen-Bjergaard J, Victor MA, Geisler CH. The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia. Leuk Res Oct. 1997;21(10):985-995.
Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18(2):115-136.
Horner PJ, Thallmair M, Gage FH. Defining the NG2-expressing cell of the adult CNS. J Neurocytol. 2002;31(6-7):469-480.
Grako KA, Stallcup WB. Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. Exp Cell Res. 1995;221(1):231-240.
Levine JM, Nishiyama A. The NG2 chondroitin sulfate proteoglycan: a multifunctional proteoglycan associated with immature cells. Perspect Dev Neurobiol. 1996;3(4):245-259.
Al-Mayhani MT, Grenfell R, Narita M, et al. NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature. Neuro Oncol. 2011;13(8):830-845.
Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ, Reisfeld RA Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan Proc Natl Acad Sci U S A 1996;93(18):9710-5, Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan.
Pankova D, Jobe N, Kratochvilova M, Buccione R, Brabek J, Rosel D. NG2-mediated rho activation promotes amoeboid invasiveness of cancer cells. Eur J Cell Biol. 2012;91(11-12):969-977.
Lopez-Millan B, Sanchez-Martinez D, Roca-Ho H, et al. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia. Leukemia. 2019;33(7):1557-1569.
Prieto C, Lopez-Millan B, Roca-Ho H, et al. NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL. Leukemia. 2018;32(3):633-644.
You WK, Yotsumoto F, Sakimura K, Adams RH, Stallcup WB. NG2 proteoglycan promotes tumor vascularization via integrin-dependent effects on pericyte function. Angiogenesis. 2014;17(1):61-76.
Bueno C, Montes R, Martin L, et al. NG2 antigen is expressed in CD34+ HPCs and plasmacytoid dendritic cell precursors: is NG2 expression in leukemia dependent on the target cell where leukemogenesis is triggered? Leukemia. 2008;22(8):1475-1478.
Menendez P, Bueno C. Expression of NG2 antigen in MLL-rearranged acute leukemias: how complex does it get? Leuk Res. 2011;35(8):989-990.
Petrovici K, Graf M, Hecht K, Reif S, Pfister K, Schmetzer H. Use of NG2 (7.1) in AML as a tumor marker and its association with a poor prognosis. Cancer Genomics Proteomics. 2010;7(4):173-180.
Lacombe F, Bernal E, Bloxham D, et al. Harmonemia: a universal strategy for flow cytometry immunophenotyping-a European LeukemiaNet WP10 study. Leukemia. 2016;30(8):1769-1772.